Physician profile
Diana Widicus
NPI 1851471072
$1,696.83
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $532 · 2021: $350.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $395.05 | 2019-2021 | |
| Lilly USA, LLC | $126.84 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $111.97 | 2019 | |
| Abbott Laboratories | $109.32 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.91 | 2019-2021 | |
| Astellas Pharma US INC | $107.76 | 2019-2021 | |
| Esperion Therapeutics, INC. | $99.47 | 2020-2021 | |
| Novo Nordisk INC | $84.79 | 2019-2021 | |
| Pfizer INC. | $76.91 | 2019-2020 | |
| Eisai INC. | $64.98 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.79 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $39.24 | 2020-2021 | |
| Amgen INC. | $33.06 | 2019-2020 | |
| Abbvie INC. | $29.89 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.53 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.22 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.68 | 2021 | |
| Genentech USA, INC. | $19.28 | 2019 | |
| Glaxosmithkline, LLC. | $16.99 | 2019 | |
| Amarin Pharma, INC. | $16.95 | 2021 | |
| Nabriva Therapeutics, Plc | $16.51 | 2020 | |
| Circassia INC. | $15.79 | 2019 | |
| Biodelivery Sciences International, INC. | $15.72 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.66 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.31 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.68 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.46 | 2019 | |
| Merck Sharp & Dohme LLC | $11.20 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Research and ownership
$64,630.02 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Widicus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.